Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Sell
33
GNOM Quote, Financials, Valuation and Earnings
Last price:
$8.33
Seasonality move
:
7.88%
Day range:
$8.31 - $8.52
52-week range:
$8.31 - $11.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
66.9K
Avg. volume:
82.2K
1-year change:
-26.63%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
$8.35 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$31.25 | -- | -- | -- | $0.15 | 0.8% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$18.66 | -- | -- | -- | $0.24 | 1.28% | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
$9.38 | -- | -- | -- | $0.00 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$27.48 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$64.15 | -- | -- | -- | $0.03 | 0.07% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.063 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.954 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.069 | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | 1.921 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.723 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.203 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
Global X Genomics & Biotechnology ETF vs. Competitors
-
Which has Higher Returns GNOM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is GNOM or AGNG More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.215, which suggesting that the stock is 21.496% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.348%.
-
Which is a Better Dividend Stock GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.8% to investors and pays a quarterly dividend of $0.15 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or AGNG?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns GNOM or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About GNOM or BBC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is GNOM or BBC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.215, which suggesting that the stock is 21.496% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, suggesting its more volatile than the S&P 500 by 7.979%.
-
Which is a Better Dividend Stock GNOM or BBC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.28% to investors and pays a quarterly dividend of $0.24 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or BBC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns GNOM or EDOC?
Global X Telemedicine & Digital Health ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Telemedicine & Digital Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- -
What do Analysts Say About GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Telemedicine & Digital Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Telemedicine & Digital Health ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Telemedicine & Digital Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 EDOCGlobal X Telemedicine & Digital Health ETF0 0 0 -
Is GNOM or EDOC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.215, which suggesting that the stock is 21.496% more volatile than S&P 500. In comparison Global X Telemedicine & Digital Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Telemedicine & Digital Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Telemedicine & Digital Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or EDOC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Telemedicine & Digital Health ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Telemedicine & Digital Health ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Telemedicine & Digital Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Telemedicine & Digital Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- --
-
Which has Higher Returns GNOM or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is GNOM or HTEC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.215, which suggesting that the stock is 21.496% more volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.126, suggesting its more volatile than the S&P 500 by 12.561%.
-
Which is a Better Dividend Stock GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HTEC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns GNOM or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About GNOM or PBE?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is GNOM or PBE More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.215, which suggesting that the stock is 21.496% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.832, suggesting its less volatile than the S&P 500 by 16.774%.
-
Which is a Better Dividend Stock GNOM or PBE?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or PBE?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
